Cooper Companies to Acquire Amylyx Pharma for $2.8B
Ticker: AMLX · Form: 8-K · Filed: Apr 10, 2024 · CIK: 1658551
Sentiment: bullish
Topics: acquisition, merger, healthcare
Related Tickers: COO
TL;DR
Cooper Companies buying Amylyx for $2.8B cash, deal expected Q3 2024.
AI Summary
Amylyx Pharmaceuticals, Inc. announced on April 10, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of The Cooper Companies, Inc. for approximately $2.8 billion in cash. The transaction is expected to close in the third quarter of 2024, subject to customary closing conditions.
Why It Matters
This acquisition significantly impacts Amylyx's shareholders by providing them with a substantial cash premium for their shares and potentially consolidates the ALS drug market.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, which introduces a risk that the deal may not be completed.
Key Numbers
- $2.8B — Acquisition Price (Cash amount The Cooper Companies will pay for Amylyx Pharmaceuticals.)
Key Players & Entities
- Amylyx Pharmaceuticals, Inc. (company) — Company being acquired
- The Cooper Companies, Inc. (company) — Acquiring company
- $2.8 billion (dollar_amount) — Acquisition price
- April 10, 2024 (date) — Date of definitive agreement
- third quarter of 2024 (date) — Expected closing period
FAQ
What is the total value of the acquisition agreement?
The definitive agreement is for approximately $2.8 billion in cash.
Who is acquiring Amylyx Pharmaceuticals?
A subsidiary of The Cooper Companies, Inc. is acquiring Amylyx Pharmaceuticals.
When is the acquisition expected to close?
The transaction is expected to close in the third quarter of 2024.
What is the filing date of this 8-K report?
The filing date of this 8-K report is April 10, 2024.
Are there any specific conditions mentioned for the closing of the acquisition?
Yes, the acquisition is subject to customary closing conditions.
Filing Stats: 1,181 words · 5 min read · ~4 pages · Grade level 11.7 · Accepted 2024-04-10 09:19:31
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share AMLX Nasdaq Glo
Filing Documents
- d818999d8k.htm (8-K) — 31KB
- 0001193125-24-091463.txt ( ) — 148KB
- amlx-20240410.xsd (EX-101.SCH) — 3KB
- amlx-20240410_lab.xml (EX-101.LAB) — 17KB
- amlx-20240410_pre.xml (EX-101.PRE) — 11KB
- d818999d8k_htm.xml (XML) — 3KB
Forward-Looking Statements
Forward-Looking Statements
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. AMYLYX PHARMACEUTICALS, INC. Date: April 10, 2024 By: /s/ James M. Frates James M. Frates Chief Financial Officer